FeesSafety
Pluang+
Home/Explore/US Market Price/Stocks/REGN
icon
Up to 4x
Us company
Asset icon - trade crypto, stocks, and gold on Pluang

Regeneron Pharmaceuticals Inc (REGN) Stock Price Today

TechnicalsFundamentalsFinancialsNewsCorp ActionAboutCompare
24H
1W
1M
3M
YTD
1Y
5Y

Aura AI Summary

Regeneron Pharmaceuticals (REGN) trades at $961.26, up 3.6% today, reflecting strong momentum after beating Q1-Q3 2026 EPS estimates. The stock exhibits a bullish technical trend with moving averages supporting upside, while fundamentals show robust profitability with a 28.5% net margin and revenue growth to $14.34B in 2025. Recent news highlights a strategic $8B immunology alliance expansion with Sanofi, enhancing long-term growth prospects.
The outlook remains positive given earnings beats, high analyst buy ratings (71%), and expanding immunology pipeline, though risks include competitive pressures in ophthalmology and reliance on key drugs. The stock trades above the consensus price target of $878.05, suggesting near-term consolidation potential amid bullish institutional sentiment.
Read full analysis

Key Stats

  • Market Cap
    $95.99B
  • Volume
    2,870,752
  • Sector
    Health
  • 52W High
    $927.89
  • 52W Low
    $600.66
  • Typical Hold Time
    108 Days
  • Enterprise Value
    $89.39B
  • Div Yield
    0.41%
  • Trading Activity
    80% Sell | 20% Buy
$963.79
52W Low: $600.66
01 Jun 2026
52W High: $963.79
02 Nov 2026

Track Regeneron Pharmaceuticals Inc (REGN) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Regeneron Pharmaceuticals Inc has traded between a low of $600.66 and a high of $963.79, highlighting its annual price range. Buy and sell Regeneron Pharmaceuticals Inc shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.

About Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases

Most Recent News

Content is generated by Aura AI

Global Indemnity delays Q3 earnings call to January, introducing new CEO Jessica Buss.

Global Indemnity Group will postpone its third quarter 2026 earnings call originally scheduled for November 4 to January, when new CEO Jessica Buss will present her vision and priorities for the company. The company will still release its Q3 results ...

Market News
26 minutes ago
Na
Neutral
Global Indemnity delays Q3 earnings call to January, introducing new CEO Jessica Buss.

Lorraine Ben joins Syntax Defence as Canada boosts defence spending over $500B in a decade

Lorraine Ben, former CEO of Lockheed Martin Canada, has joined Syntax Defence to provide expert counsel amid Canada's commitment to invest over half a trillion dollars in defence over the next decade. This includes $180 billion in procurement opportu...

Market News
58 minutes ago
Not Specified
Bullish
news icon
Lorraine Ben joins Syntax Defence as Canada boosts defence spending over $500B in a decade

Alamar Biosciences and Nightingale Health launch 80,000-sample UK Biobank study on early neurodegenerative disease detection.

Alamar Biosciences and Nightingale Health have initiated the UK Biobank PRISM study, analyzing 80,000 blood samples to identify early protein biomarkers linked to neurodegenerative diseases like Parkinson's and Alzheimer's. Using Alamar's sensitive N...

Market News
5 hours ago
GlobeNewsWire
Bullish
news icon
Alamar Biosciences and Nightingale Health launch 80,000-sample UK Biobank study on early neurodegenerative disease detection.
Catch up fast with Aura AI
Get an AI-generated news summary for this asset in seconds.

People also bought

Frequently Asked Questions

US stocks trading hours: Monday - Friday (Except for US public holidays) Time: 21.30 - 04.00 WIB 20.30 - 03.00 WIB (Daylight Savings Time*) *The next Daylight Savings is scheduled to begin on March 13, 2022 and ends on November 6, 2022. You can place limit orders outside of the trading hours, but it can only be executed during trading hours. For illustration, a stock is currently trading at $10 per share, but you only want to pay $7 per share at most. Let’s say you set your limit price to $7 at 18.00. Your order will be executed when the market is open at 21.30 if the stock drops from $10 to $7 or lower. Similarly, if the stock price doesn’t drop to $7, your order won’t be executed.
Yes, you are eligible to receive dividend payment if and when the company pays them on one condition: minimum net dividend paid is at least $0.01. Net dividend is gross dividend subtracted by 15% withholding tax.
Yes, it is. US Stocks risk is managed by PT PG Berjangka which is licensed by Badan Pengawas Perdagangan Berjangka Komoditi (BAPPEBTI), and your investment is guaranteed by Jakarta Futures Exchange (JFX) and Indonesian Clearing House (KBI).
Pluang charges a fixed transaction fee of 0.30% for regular users and 0.20% for Pluang Plus members, including VAT to cover the exchange fees and operational costs.
US Stocks, ETFs, and Options are facilitated by PT PG Berjangka in its capacity as a Licensed Derivatives Broker supervised by the Financial Services Authority of Indonesia (OJK) for financial derivative products with underlying securities. All transactions are recorded on the Jakarta Futures Exchange (JFX) and the Indonesian Futures Clearing House (KBI). In addition, PT PG Berjangka is also a Licensed Futures Broker supervised by the Commodity Futures Trading Regulatory Agency (Bappebti). Read our product’s Terms and Conditions

All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.

Key Stats

  • Market Cap
    $95.99B
  • Volume
    2,870,752
  • Sector
    Health
  • 52W High
    $927.89
  • 52W Low
    $600.66
  • Typical Hold Time
    108 Days
  • Enterprise Value
    $89.39B
  • Div Yield
    0.41%
  • Trading Activity
    80% Sell | 20% Buy
$963.79
52W Low: $600.66
01 Jun 2026
52W High: $963.79
02 Nov 2026

Track Regeneron Pharmaceuticals Inc (REGN) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Regeneron Pharmaceuticals Inc has traded between a low of $600.66 and a high of $963.79, highlighting its annual price range. Buy and sell Regeneron Pharmaceuticals Inc shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.

Let’s invest in this asset by signing up or download!